The NIH have IOU to repay to Synairgen if P3 trial ends well.19 Oct 2021 22:29
NIH need to give a lot of attention on a positive Synairgen trial result in a few weeks time if efficacy and benefits is proved to be very effective. If not the disparity in conjunction with today's observations implies bias and prejudice. It may lead to suggestions that NIH is as bad as the Federal reserve with committee members actively trading stocks and cover positions to their personal advantage over everyone else (3 out of 12 have been implicated with insider trading). Senator Warren has shown up the FED committee and now it has lost public confidence and Trust in the USA and globally on quite a significant scale. With many Americans losing their jobs for not having a vaccination to Covid-19, the NIH can not afford a similar loss of public trust or confidence.
For the time being Synairgen has to deliver its trial results and establish if those results are very good. If so, we hope that NIH will level up on today's poor choice of editing and they support good science robustly and deliver on good care to the health of their citizens, especially if Synairgen interferon beta immunomodulator through a nebuliser with direct delivery to lung tissue is the best answer in the Covid-19 therapy toolbox.